Caution about ketoacidosis, UTIs, and other serious ADRs with the SGLT2s

February 2016

More warnings for the SGLT2 inhibitors (Invokana, etc) will increase concerns about their safety.

These "flozins" are sometimes preferred because they have a low risk of hypoglycemia...lead to modest weight loss...and can lower BP.

Plus Jardiance (empagliflozin) has CV benefits including a reduced risk of cardiovascular death and heart failure hospitalizations.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology Prevent Med-Related Problems to Reduce Heart Failure Readmissions
New Generics Alert Your Patients to Their Meds That Will Go Generic in 2016
Neurology & Pain Don't Jump to Belbuca Before Non-Opioids for Chronic Pain
Diabetes Caution about ketoacidosis, UTIs, and other serious ADRs with the SGLT2s
Diabetes Caution "Third-Party" Test Strips Don't Work With Most Glucose Meters
COPD Explain How Seebri and Utibron Stack Up Against Other Inhalers for COP
Vaccines Give injections in the right spot to avoid shoulder injuries
Fall Risk Caution About Falls with SELECTIVE Alpha-blockers
Cough & Cold Avoid ORAL Phenylephrine...but Suggest INTRANASAL for Some
Anticoagulants Don't Delay Restarting Anticoagulation in Atrial Fib Patients After GI Bleeding
Women's Health Don't Always Shun SSRIs During Pregnancy
Hepatitis C Be Aware of Possible Liver Failure with Viekira Pak or Technivie
Hyperkalemia Suggest Low-Cost Treatments for High Potassium